HIV Disclosure and Medication Adherence, a Pilot Study (RSAD-VIH-11)
The investigators believe that disclosure of HIV status could influence medication adherence. If disclosure leads to social support, adherence could be improved. This study purpose is to assess correlation between disclosure and medication adherence, and to describe people whose HIV status has been disclosed to.
|Study Design:||Observational Model: Cohort
Time Perspective: Cross-Sectional
|Official Title:||HIV Disclosure and Medication Adherence, a Pilot Study|
- Patient Adherence [ Time Frame: 30 days before survey ] [ Designated as safety issue: No ]Electronic monitoring of adherence during 30 days before survey
- Patient Adherence [ Time Frame: 90 days before survey ] [ Designated as safety issue: No ]Electronic monitoring of adherence during 90 days before survey
|Study Start Date:||April 2012|
|Estimated Study Completion Date:||March 2013|
|Estimated Primary Completion Date:||November 2012 (Final data collection date for primary outcome measure)|
Pharmacists administer a questionnaire to each consecutive subject taking part in the adherence-enhancing program at the pharmacy of the Department of Ambulatory Care And Community Medicine in Lausanne. This questionnaire assesses disclosure, response to disclosure, and living situation.
Adherence is measured by electronic monitoring and pill count.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01621412
|Policlinique Médicale Universitaire|
|Lausanne, Vaud, Switzerland, 1011|
|Principal Investigator:||Marie-Paule Schneider, PhD||Policlinique Médicale Universitaire|
|Principal Investigator:||Aurélie Gertsch, PhD-Student||Policlinique Médicale Universitaire|
|Study Chair:||Olivier Bugnon, Professor||Policlinique Médicale Universitaire|
|Study Chair:||Matthias Cavassini, MD||Centre Hospitalier Universitaire Vaudois|